Mobocertinib

CHEMBL4650319 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

585.7 g/mol

LogP

4.4

Phase

4

This tyrosine kinase inhibitor is specifically designed to target a particular mutation in the EGFR gene—exon 20 insertions—that occurs in a subset of non-small cell lung cancer patients who do not respond well to standard EGFR inhibitors. It provides a targeted treatment option for this previously difficult-to-treat lung cancer subgroup.

Berat Molekul

585,7000 g/mol

LogP

4,40

TPSA

114,00 Å²

Lipinski RO5

Lulus

Area Terapeutik

Non-Small Cell Lung Cancer

Mekanisme Kerja

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer …

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C

InChI

InChI=1S/C32H39N7O4/c1-9-29(40)34-24-16-25(28(42-8)17-27(24)38(6)15-14-37(4)5)35-32-33-18-22(31(41)43-20(2)3)30(36-32)23-19-39(7)26-13-11-10-12-21(23)26/h9-13,16-20H,1,14-15H2,2-8H3,(H,34,40)(H,33,35,36)

Molecular Formula

C32H39N7O4

HBD / HBA

2 / 9

Ikatan yang Dapat Dirotasi

13

Atom Berat

43

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

This tyrosine kinase inhibitor is specifically designed to target a particular mutation in the EGFR gene—exon 20 insertions—that occurs in a subset of non-small cell lung cancer patients who do not respond well to standard EGFR inhibitors. It provides a targeted treatment option for this previously difficult-to-treat lung cancer subgroup.

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Yes, Mobocertinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4650319. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 118607832. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Mencari informasi yang ramah bagi pasien?

Mobocertinib di PillFYI

Struktur

Data Cepat

Rumus: C32H39N7O4

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.